A total of 87 percent of patients in the placebo group completed treatment, as did 82 percent, 77 percent, and 62 percent in the 200, 400, and 600 mg/day Vimpat(R) groups.
Summary of Vimpat(R) Data Presented at 2008 AES Annual Meeting
Early Onset of Efficacy in the Initial Weeks of Treatment with Lacosamide: A Pooled Analysis of Three Phase II/III Trials
This analysis found that Vimpat(R) demonstrated statistically significant efficacy as early as the first week of treatment, with consistently significant results for both primary endpoints starting at doses of 100 mg/day.
-- At the end of the first week of treatment in this study, when all participants in the active treatment groups were receiving 100 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (33.0 percent Vimpat(R) group vs. 19.4 percent placebo; p<.01). Also during the first week, 39.1 percent of patients treated with Vimpat(R) experienced a 50 percent or greater reduction in seizures, compared with 31.3 percent in the placebo group (p<.01).
-- By the end of the second week of treatment, when all participants in the treatment groups were receiving 200 mg/day of Vimpat(R), a significant reduction in seizure frequency was observed versus placebo (34.0 percent Vimpat(R) group vs. 20.0 percent placebo; p<.01). The percentage of patients with a 50 percent or greater reduction in seizure frequency was 40.2% for patients receiving Vimpat(R) and 32.2 percent for placebo (p<.01 vs. placebo).
-- These significant seizure reductions appeared to be maintained over subsequent weeks of Vimpat(R) treatment.
Poster Session 3, December 8, 2008, 8:00 - 9:00 am (Poster 3.256) Michael Sperling, MD, David Rudd, PharmD, David Hebert, PhD, Pamela Doty, PhD Thomas Jefferson Universit
Copyright©2008 PR Newswire.
All rights reserved